TABLE OF CONTENTS
1 INTRODUCTION 85
1.1 OBJECTIVES OF THE STUDY 85
1.2 MARKET DEFINITION 85
1.3 OVERVIEW OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET 85
1.4 CURRENCY AND PRICING 87
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 TYPE LIFELINE CURVE 98
2.8 DBMR MARKET POSITION GRID 99
2.9 VENDOR SHARE ANALYSIS 101
2.10 MARKET END-USER COVERAGE GRID 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHT 107
4.1 PESTEL ANALYSIS 108
4.2 PORTERS FIVE FORCES 109
5 EPIDEMIOLOGY 110
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA 111
7 INDUSTRY INSIGHTS: 112
8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, REGULATION 113
9 MARKET OVERVIEW 116
9.1 DRIVERS 118
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA 118
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE 118
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS 119
9.2 RESTRAINTS 120
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA 120
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES 121
9.3 OPPORTUNITIES 121
9.3.1 GROWING AGING POPULATION 121
9.3.2 RISE IN THE DRUG APPROVAL 122
9.4 CHALLENGES 123
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION 123
9.4.2 STRINGENT REGULATIONS 123
10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE 124
10.1 OVERVIEW 125
10.2 NON-ULCER DYSPEPSIA 128
10.3 ORGANIC DYSPEPSIA 128
10.4 DRUG INDUCED DYSPEPSIA 129
10.5 OTHERS 130
11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE 131
11.1 OVERVIEW 132
11.2 MEDICATION 135
11.2.1 DRUGS 136
11.2.1.1 ANTACIDS 136
11.2.1.1.1 PROTON PUMP INHIBITORS (PPIS) 136
11.2.1.1.1.1 OMEPRAZOLE 137
11.2.1.1.1.2 LANSOPRAZOLE 137
11.2.1.1.1.3 ESOMEPRAZOLE 137
11.2.1.1.1.4 OTHERS 137
11.2.1.1.2 H2 BLOCKERS 137
11.2.1.1.2.1 CIMETIDINE 138
11.2.1.1.2.2 FAMOTIDINE 138
11.2.1.1.2.3 NIZATIDINE 138
11.2.1.1.2.4 RANITIDINE 138
11.2.1.1.2.5 OTHERS 138
11.2.1.2 GASTRIC PROKINETIC GENDERNTS 138
11.2.1.2.1 MOSAPRIDE CITRATE 139
11.2.1.2.2 METOCLOPRAMIDE 139
11.2.1.2.3 CISAPRIDE 139
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE 139
11.2.1.2.5 DOMPERIDONE 139
11.2.1.2.6 OTHERS 140
11.2.1.3 ANTIBIOTICS 140
11.2.1.3.1 REFAXIMIN 140
11.2.1.3.2 AMOXICILLIN 140
11.2.1.3.3 CLARITHROMYCIN 140
11.2.1.3.4 METRONIDAZOLE 141
11.2.1.3.5 LEVOFLOXACIN 141
11.2.1.3.6 TETRACYCLINE 141
11.2.1.3.7 OTHERS 141
11.2.1.4 OTHERS 141
11.2.2 NON- DRUGS 141
11.2.2.1 PROBIOTICS 141
11.2.2.1.1 LACTOBACILLUS 142
11.2.2.1.2 BIFIDOBACTERIUM 142
11.2.2.1.3 BACILLUS 142
11.2.2.1.4 STREPTOCOCCUS 142
11.2.2.1.5 OTHERS 142
11.2.2.2 PREBIOTICS 142
11.3 SURGERY 143
12 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE 144
12.1 OVERVIEW 145
12.2 GENERIC 148
12.3 BRANDED 149
13 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION 150
13.1 OVERVIEW 151
13.2 WITHOUT PRESCRIPTION DRUGS 154
13.3 PRESCRIPTION DRUGS 155
14 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION 156
14.1 OVERVIEW 157
14.2 ORAL 160
14.2.1 TABLETS 160
14.2.2 CAPSULES 161
14.3 INJECTABLE 161
15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER 162
15.1 OVERVIEW 163
15.2 FEMALE 166
15.2.1 30-50 YEARS 167
15.2.2 MORE THAN 50 YEARS 167
15.2.3 AGE LESS THAN 30 167
15.3 MALE 167
15.3.1 30-50 YEARS 168
15.3.2 MORE THAN 50 YEARS 168
15.3.3 AGE LESS THAN 30 168
16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER 169
16.1 OVERVIEW 170
16.2 HOSPITALS 173
16.2.1 TYPE 173
16.2.1.1 PUBLIC 174
16.2.1.2 PRIVATE 174
16.2.2 TIER 174
16.2.2.1 TIER 3 174
16.2.2.2 TIER 2 174
16.2.2.3 TEIR 1 174
16.3 CLINICS 174
16.4 HOMECARE SETTINGS 175
16.5 SPECIALTY CLINICS 176
16.6 AMBULATORY CENTERS 177
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 177
16.8 OTHERS 178
17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL 179
17.1 OVERVIEW 180
17.2 RETAIL SALES 183
17.2.1 REATIL PHARMACY 184
17.2.2 HOSPITAL PHARMACY 184
17.2.3 ONLINE PHARMACY 184
17.3 DIRECT TENDER 184
18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY REGION 185
18.1 ASIA-PACIFIC 186
18.1.1 JAPAN 201
18.1.2 CHINA 212
18.1.3 SOUTH KOREA 223
18.1.4 INDIA 234
18.1.5 AUSTRALIA 244
18.1.6 NEW ZEALAND 255
18.1.7 SINGAPORE 267
18.1.8 THAILAND 278
18.1.9 INDONESIA 289
18.1.10 MALAYSIA 300
18.1.11 PHILIPPINES 311
18.1.12 VIETNAM 322
18.1.13 TAIWAN 333
18.1.14 REST OF ASIA-PACIFIC 344
19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE 345
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 345
20 SWOT ANALYSIS 346
21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS 347
21.1 SANOFI 347
21.1.1 COMPANY SNAPSHOT 347
21.1.2 REVENUE ANALYSIS 347
21.1.3 COMPANY SHARE ANALYSIS 348
21.1.4 PRODUCT PORTFOLIO 348
21.1.5 RECENT DEVELOPMENT 348
21.2 LUPIN 349
21.2.1 COMPANY SNAPSHOT 349
21.2.2 REVENUE ANALYSIS 349
21.2.3 COMPANY SHARE ANALYSIS 350
21.2.4 PRODUCT PORTFOLIO 350
21.2.5 RECENT DEVELOPMENTS 350
21.3 MANKIND PHARMA 351
21.3.1 COMPANY SNAPSHOT 351
21.3.2 REVENUE ANALYSIS 351
21.3.3 COMPANY SHARE ANALYSIS 352
21.3.4 PRODUCT PORTFOLIO 352
21.3.5 RECENT DEVELOPMENT 352
21.4 ASTRAZENECA 353
21.4.1 COMPANY SNAPSHOT 353
21.4.2 REVENUE ANALYSIS 353
21.4.3 COMPANY SHARE ANALYSIS 354
21.4.4 PRODUCT PORTFOLIO 354
21.4.5 RECENT DEVELOPMENT 354
21.5 BAYER AG 355
21.5.1 COMPANY SNAPSHOT 355
21.5.2 REVENUE ANALYSIS 355
21.5.3 COMPANY SHARE ANALYSIS 356
21.5.4 PRODUCT PORTFOLIO 356
21.5.5 RECENT DEVELOPMENT 356
21.6 ABBOTT 357
21.6.1 COMPANY SNAPSHOT 357
21.6.2 REVENUE ANALYSIS 357
21.6.3 PRODUCT PORTFOLIO 358
21.6.4 RECENT DEVELOPMENT 358
21.7 ANI PHARMACEUTICALS, INC. 359
21.7.1 COMPANY SNAPSHOT 359
21.7.2 REVENUE ANALYSIS 359
21.7.3 PRODUCT PORTFOLIO 360
21.7.4 RECENT DEVELOPMENT 360
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD. 361
21.8.1 COMPANY SNAPSHOT 361
21.8.2 REVENUE ANALYSIS 361
21.8.3 PRODUCT PORTFOLIO 362
21.8.4 RECENT DEVELOPMENT 362
21.9 ASTERISK LABORATORIES (I) PVT. LTD 363
21.9.1 COMPANY SNAPSHOT 363
21.9.2 PRODUCT PORTFOLIO 363
21.9.3 RECENT DEVELOPMENT 363
21.10 CADILA PHARMACEUTICALS 364
21.10.1 COMPANY SNAPSHOT 364
21.10.2 REVENUE ANALYSIS 364
21.10.3 COMPANY SHARE ANALYSIS 365
21.10.4 PRODUCT PORTFOLIO 365
21.10.5 RECENT DEVELOPMENT 365
21.11 HANMI PHARM. CO., LTD. 366
21.11.1 COMPANY SNAPSHOT 366
21.11.2 REVENUE ANALYSIS 366
21.11.3 PRODUCT PORTFOLIO 367
21.11.4 RECENT DEVELOPMENT 367
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 368
21.12.1 COMPANY SNAPSHOT 368
21.12.2 REVENUE ANALYSIS 368
21.12.3 PRODUCT PORTFOLIO 369
21.12.4 RECENT DEVELOPMENT 369
21.13 OTSUKA PHARMACEUTICAL CO., LTD. 370
21.13.1 COMPANY SNAPSHOT 370
21.13.2 REVENUE ANALYSIS 370
21.13.3 PRODUCT PORTFOLIO 371
21.13.4 RECENT DEVELOPMENT 371
21.14 PERRIGO COMPANY PLC 372
21.14.1 COMPANY SNAPSHOT 372
21.14.2 REVENUE ANALYSIS 372
21.14.3 PRODUCT PORTFOLIO 373
21.14.4 RECENT DEVELOPMENT 373
21.15 PRESTIGE CONSUMER HEALTHCARE, INC. 374
21.15.1 COMPANY SNAPSHOT 374
21.15.2 REVENUE ANALYSIS 374
21.15.3 PRODUCT PORTFOLIO 375
21.15.4 RECENT DEVELOPMENT 375

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.